In well-performed studies in therapy-related MDS/AML, it was found that cells harboring the leukemia-specific TP53 mutation preexisted to the first cancer and were positively selected by treatment for this cancer (chemotherapy or radiation) to which they were resistant [55,56]. This evidence concerns the gene TP53 and acute myeloid leukemia.